NANOVIRICIDES, INC. Contracts & Agreements
102 Contracts & Agreements
- Business Finance (61 contracts)
- Business Operations (5)
- Human Resources (13)
- Intellectual Property (4)
- Real Estate (1)
- Uncategorized (18)
- At Market Issuance Sales Agreement by and between NanoViricides, Inc. and EF Hutton LLC (Filed With SEC on April 5, 2024)
- Amendment to License Agreement between the Company and TheraCour, dated February 13, 2024 (Filed With SEC on February 16, 2024)
- Line of Credit Agreement between the Company and Dr. Anil R. Diwan, dated November 13, 2023 (Filed With SEC on February 16, 2024)
- Extension Agreement between the Company and Dr. Anil R. Diwan, dated February 12, 2024 (Filed With SEC on February 16, 2024)
- Letter from TheraCour Pharma, Inc (Filed With SEC on February 16, 2024)
- Extension to Employment Agreement with A. Diwan effective July 1, 2023 (Filed With SEC on October 13, 2023)
- Extension to CFO Agreement with Meeta Vyas effective July 1, 2023 (Filed With SEC on October 13, 2023)
- Deferred Expense Exchange Agreement between the Registrant and TheraCour effective July 19, 2023 (Filed With SEC on September 1, 2023)
- Convertible Promissory Note between the Registrant and TheraCour, effective July 19, 2023 (Filed With SEC on September 1, 2023)
- Form of Plan of Conversion (Filed With SEC on May 25, 2023)
- License Agreement between the Company and Karveer (Filed With SEC on March 31, 2023)
- Extension of Employment Agreement with Anil Diwan (Filed With SEC on October 11, 2022)
- Coronavirus License Agreement with TheraCour Pharma, Inc (Filed With SEC on September 15, 2021)
- Extension of Employment Agreement with Anil Diwan (Filed With SEC on September 15, 2021)
- Form of Director Retainer Agreement (Filed With SEC on November 19, 2020)
- At Market Issuance Sales Agreement by and between NanoViricides, Inc., B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc., dated... (Filed With SEC on August 3, 2020)
- Underwriting Agreement with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. dated July 8, 2020 (Filed With SEC on July 13, 2020)
- Form of Securities Purchase Agreement dated May 21, 2020 by and between NanoViricides, Inc. and certain purchasers (Filed With SEC on May 22, 2020)
- Placement Agent Agreement, dated May 21, 2020 by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc (Filed With SEC on May 22, 2020)
- Director Retainer Agreement, dated as of May 15, 2020, between the Company and Mr. Rokita (Filed With SEC on May 19, 2020)
- Form of Director Retainer Agreement (Filed With SEC on February 11, 2020)
- Form of Settlement Agreement and Mutual Release (Filed With SEC on January 28, 2020)
- Form of Exchange Agreement (Filed With SEC on January 28, 2020)
- Form of Common Stock Purchase Agreement (Filed With SEC on January 28, 2020)
- Underwriting with Aegis Capital Corp. dated January 21, 2020 (Filed With SEC on January 27, 2020)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 8, 2020)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 8, 2020)
- Employment Agreement with M Vyas (Filed With SEC on January 8, 2020)
- Form of Series A Conversion Waiver (Filed With SEC on January 8, 2020)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 7, 2020)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 7, 2020)
- Employment Agreement with M Vyas (Filed With SEC on January 7, 2020)
- Form of Series A Conversion Waiver (Filed With SEC on January 7, 2020)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 23, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 23, 2019)
- Employment Agreement with M Vyas (Filed With SEC on December 23, 2019)
- Form of Series A Conversion Waiver (Filed With SEC on December 23, 2019)
- Open End Mortgage Note (Filed With SEC on December 19, 2019)
- Open End Mortgage Deed (Filed With SEC on December 19, 2019)
- Deferred Expense Exchange Agreement (Filed With SEC on December 19, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 17, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 17, 2019)
- Employment Agreement with M Vyas (Filed With SEC on December 17, 2019)
- Form of Series A Conversion Waiver (Filed With SEC on December 17, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on November 29, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on November 29, 2019)
- Employment Agreement with M Vyas (Filed With SEC on November 29, 2019)
- Form of Series A Conversion Waiver (Filed With SEC on November 29, 2019)
- License Agreement with TheraCour Pharma, Inc (Filed With SEC on November 6, 2019)
- Form of Underwriting Agreement (Filed With SEC on September 27, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on September 27, 2019)
- Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on September 27, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on September 27, 2019)
- Form of Common Stock Purchase Warrant (Filed With SEC on September 27, 2019)
- Form of Representatives Warrant (Filed With SEC on September 27, 2019)
- Employment Agreement with M Vyas (Filed With SEC on September 27, 2019)
- Form of Series A Conversion Waiver (Filed With SEC on September 27, 2019)
- Director Retainer Agreement (Filed With SEC on June 10, 2019)
- Form of Securities Purchase Agreement dated February 27, 2019 by and between NanoViricides, Inc. and certain purchasers (Filed With SEC on March 1, 2019)
- Form of Common Stock Purchase Warrant (Filed With SEC on March 1, 2019)
- Placement Agent Agreement, dated February 27, 2019, by and between NanoViricides. and Chardan Capital Markets, LLC (Filed With SEC on March 1, 2019)
- Director Retainer Agreement (Filed With SEC on October 31, 2018)
- A. Diwan Employment Agreement (Filed With SEC on July 23, 2018)
- I. Taraporewala Employment Agreement (Filed With SEC on July 23, 2018)
- A Diwan Employment Agreement (Filed With SEC on July 19, 2018)
- Form of Warrant (Filed With SEC on May 4, 2018)
- Confidential Separation Agreement and General Release (Filed With SEC on May 4, 2018)
- CONVERSION AND SETTLEMENT AGREEMENT (Filed With SEC on February 13, 2017)
- AGREEMENT OF PURCHASE AND SALE (Filed With SEC on January 7, 2015)
- ******************** (Filed With SEC on January 24, 2014)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 24, 2014)
- COMMON STOCK PURCHASE WARRANT (Filed With SEC on January 24, 2014)
- ******************** (Filed With SEC on September 13, 2013)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on September 13, 2013)
- COMMON STOCK PURCHASE WARRANT __________ (Filed With SEC on September 13, 2013)
- First Amendmentto SECURITIESPURCHASE AGREEMENT (Filed With SEC on December 27, 2012)
- CERTIFICATE OF DESIGNATION, RIGHTS ANDPREFERENCES OF SERIES C CONVERTIBLE PREFERRED STOCK OF NANOVIRICIDES, INC. (Continued) (Filed With SEC on July 2, 2012)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 2, 2012)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on June 29, 2012)
- Amendment to Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on November 3, 2011)
- Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on November 3, 2011)
- Underwriter Agent Agreement Amendment No. 1 (Filed With SEC on April 19, 2011)
- Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on April 19, 2011)
- Securities Purchase Agreement dated April 5, 2011 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on April 19, 2011)
- Amended Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on September 22, 2010)
- Letter Agreement and Amendment with respect to Follow-On Offering pursuant to that certain Securities Purchase Agreement, dated as of May 11, 2010, by and between NanoViricides,... (Filed With SEC on September 22, 2010)
- Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC (Filed With SEC on May 12, 2010)
- Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on May 12, 2010)
- Securities Purchase Agreement dated May 11, 2010 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on May 12, 2010)
- Form of Subscription Agreement of June 2009 Unit Offering (Filed With SEC on October 5, 2009)
- Form of Subscription Agreement of June 2009 Warrant Exercise Offering (Filed With SEC on October 5, 2009)
- Form of Subscription Agreement (Filed With SEC on July 10, 2009)
- Form of Common Stock Purchase Warrant (Filed With SEC on July 10, 2009)
- Form of Subscription Agreement (Filed With SEC on August 29, 2008)
- Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on August 29, 2008)
- Form of Subscription Agreement to Exercise $2.50 Warrants (Filed With SEC on August 29, 2008)
- Form of Subscription Agreement to Exercise $1.00 Warrants (Filed With SEC on August 29, 2008)
- Form of Subscription Agreement (Filed With SEC on October 18, 2007)
- Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on October 18, 2007)
- Investor Subscription Agreement dated September 21, 2007 between NanoViricides, Inc. and DKR Saturn Event Driven Holding Fund Ltd (Filed With SEC on September 27, 2007)
- Registration Rights Agreement dated September 21, 2007 between NanoViricides, Inc. and DKR Saturn Event Driven Holding Fund Ltd (Filed With SEC on September 27, 2007)
- Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on September 27, 2007)